Successful outcome of Epstein-Barr virus encephalitis managed with bilateral craniectomy, corticosteroids and aciclovir. by Hayton, E, Wakerley, B, Bowler, I, Bogdanovic, M, Adcock, J

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping by Borthwick, N, Ahmed, T, Ondondo, B, Hayton, E, Nicosia, A, McMichael, A, Dorrell, L, Hanke, T

Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type... by Hayton, E, Rose, A, Ibrahimsa, U, Del Sorbo, M, Capone, S, Crook, A, Black, A, Dorrell, L, Hanke, T

Targeting HIV-1 Where It Hurts by Ahmed, T, Hayes, P, Borthwick, N, Ondondo, B, Hayton, E, Colloca, S, Nicosia, A, McMichael, A, Gilmour, J, Dorrell, L, Hanke, T

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial by Ondondo, B, Ahmed, T, Nicola, B, Hayton, E, Vasilyeva, E, Frahm, N, Colloca, S, Nicosia, A, McMichael, A, Dorrell, L, Hanke, T

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1 by Ahmed T, Borthwick N, Yang H, Hancock G, Yorke L, Ebrahimsa U, Rose A, Black A, Hayton E, McMichael A, Dorrell L, Hanke T

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1 by Ahmed, T, Borthwick, N, Yang, H, Hancock, G, Yorke, L, Ebrahimsa, U, Rose, A, Black, A, Hayton, E, McMichael, A, Dorrell, L, Hanke, T

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial by Hanke, T, Borthwick, N, Ahmed, T, Hayton, E, Ebrahimsa, U, Rose, A, Black, A, Yang, H, Hancock, G, Colloca, S, Nicosia, A, Mcmichael, A, Dorrell, L

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial by Borthwick NJ, Ahmed T, Rose A, Ebrahimsa U, Black A, Hayton E, Yang H, Hancock G, Campion S, Frahm N, Colloca S, Nicosia A, McMichael A, Dorrell L, Hanke T

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial by Borthwick, N, Ahmed, T, Rose, A, Ebrahimsa, U, Black, A, Hayton, E, Yang, H, Hancock, G, Campion, S, Frahm, N, Colloca, S, Nicosia, A, McMichael, A, Dorrell, L, Hanke, T

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects by Hancock, G, Morón-López, S, Kopycinski, J, Puertas, M, Giannoulatou, E, Rose, A, Salgado, M, Hayton, E, Crook, A, Morgan, C, Angus, B, Chen, F, Yang, H, Martinez-Picado, J, Hanke, T, Dorrell, L

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1 by Borthwick, N, Ahmed, T, Ondondo, B, Hayes, P, Rose, A, Ebrahimsa, U, Hayton, E, Black, A, Bridgeman, A, Rosario, M, Hill, A, Berrie, E, Moyle, S, Frahm, N, Cox, J, Colloca, S, Nicosia, A, Gilmour, J, Mcmichael, A, Dorrell, L, Hanke, T

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. by Borthwick, N, Ahmed, T, Ondondo, B, Hayes, P, Rose, A, Ebrahimsa, U, Hayton, E, Black, A, Bridgeman, A, Rosario, M, Hill, A, Berrie, E, Moyle, S, Frahm, N, Cox, J, Colloca, S, Nicosia, A, Gilmour, J, McMichael, A, Dorrell, L, Hanke, T